Journal News

New tool matches microbial and metabolic metaproteomic data

Ecem Arpaci
By Ecem Arpaci
April 30, 2025

Metaproteomics is the study of all proteins expressed in entire communities, such as soil and gut microbiomes, and often requires bioinformatics approaches to analyze large quantities of data. However, until recently, none of these tools mapped protein or peptide data onto information about their biological functions.

To address this gap, in a recent study in Molecular & Cellular Proteomics, Tibo Vande Moortele of Ghent University and an international team of researchers created PathwayPilot. This bioinformatics resource combines proteomic data, including protein identification and abundances, with metabolic pathway data. Users can upload peptide or protein data, choose their desired pathways for analysis and export the results in various formats for further analysis. This makes it easier for researchers to identify the biochemical functions of proteins between organisms in a microbial community or between communities. The team tested PathwayPilot’s accuracy by analyzing data from a study on lipid metabolism and found that nearly all results matched to a known pathway.

Researchers can use this tool to compare the metaproteomic effects of environmental factors such as temperature or determine the role of a microorganism in its community, with promising applications in medical microbiology and ecology. PathwayPilot currently can only be used to compare two groups, so the team plans to continue updating the resource.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Ecem Arpaci
Ecem Arpaci

Ecem Arpaci is a biochemistry student at Imperial College London and a research intern at Radboud University Medical Center. She is an ASBMB Today volunteer contributor.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Mass spec method captures proteins in native membranes
Journal News

Mass spec method captures proteins in native membranes

Nov. 25, 2025

Yale scientists developed a mass spec protocol that keeps proteins in their native environment, detects intact protein complexes and tracks drug binding, offering a clearer view of membrane biology.

Laser-assisted cryoEM method preserves protein structure
Journal News

Laser-assisted cryoEM method preserves protein structure

Nov. 25, 2025

University of Wisconsin–Madison researchers devised a method that prevents protein compaction during cryoEM prep, restoring natural structure for mass spec studies. The approach could expand high-resolution imaging to more complex protein systems.

Method sharpens proteome-wide view of structural changes
Journal News

Method sharpens proteome-wide view of structural changes

Nov. 25, 2025

Researchers developed a method that improves limited proteolysis coupled with mass spectrometry, separating true changes from abundance or splicing effects.

Discoveries made possible by DNA
Feature

Discoveries made possible by DNA

Nov. 24, 2025

The discovery of DNA’s double helix revealed how genetic information is stored, copied and expressed. Revisit that breakthrough and traces how it laid the foundation for modern molecular biology, genomics and biotechnology.

Unraveling the language of histones
Profile

Unraveling the language of histones

Nov. 20, 2025

Philip Cole presented his research on how posttranslational modifications to histones are involved in gene expression and how these modifications could be therapeutically targeted to treat diseases like cancer.

How Alixorexton could transform narcolepsy treatment
News

How Alixorexton could transform narcolepsy treatment

Nov. 18, 2025

A new investigational drug, alixorexton, targets the brain’s orexin system to restore wakefulness in people with narcolepsy type 1. Alkermes chemist Brian Raymer shares how molecular modeling turned a lab idea into a promising phase 3 therapy.